Cancer immunotherapy with oncolytic myxoma virus

Area of Science:

• Oncolytic virotherapy
• Cancer immunotherapy
• Viral oncology

Background:

• Oncolytic viruses (OVs) are engineered to selectively target and destroy cancer cells.
• OVs can modify the tumor microenvironment to enhance anti-cancer immune responses.
• Myxoma virus (MYXV) is a promising candidate OV due to its natural tropism for cancer cells and its large, modifiable genome.

Purpose of the Study:

• To review the development of MYXV as an oncolytic immunotherapy agent.
• To highlight MYXV's potential in various preclinical cancer models.
• To discuss MYXV's mechanisms of action and therapeutic advantages.

Main Methods:

• Engineering MYXV by deleting non-essential genes and inserting immunostimulatory transgenes.
• Administering engineered MYXV systemically and locally.
• Evaluating MYXV's efficacy in preclinical cancer models.

Main Results:

• MYXV selectively infects cancer cells, sparing normal cells.
• Engineered MYXV reverses tumor immunosuppression and promotes immune cell infiltration.
• MYXV has demonstrated efficacy in preclinical models of pancreatic cancer, glioblastoma, ovarian cancer, melanoma, small cell lung cancer, and hematological malignancies.

Conclusions:

• MYXV is a versatile oncolytic immunotherapy agent with significant potential for cancer treatment.
• Its ability to target cancer cells and modulate the immune system makes it a promising therapeutic candidate.
• Further development of MYXV holds promise for improving cancer treatment outcomes.